This page maps the global competitive landscape for each therapeutic indication where ASX-listed biotechs have active pipeline assets. Competitor trials are sourced from ClinicalTrials.gov (Phase 2+, active/recruiting, non-ASX sponsors only) and approved drugs from OpenFDA (NDA/BLA approvals). Data is refreshed weekly via fetch_competitors.py.
Competitive Pressure is a weighted score: each approved drug in the indication adds 30 pts; Phase 4 trials add 20 pts each, Phase 3 adds 15 pts, Phase 2/3 adds 10 pts, and Phase 2 adds 5 pts. Thresholds: High ≥ 60 · Medium 25–59 · Low< 25. This is a directional signal only — it does not account for mechanism differentiation, patient population overlap, or commercial positioning.